NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced a new partnership with ŌURA, maker of the world’s leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team decision-support process—from preconception to menopause—Progyny is engaging membe ...

据了解，RingConn智能戒指于2022年在海外开展销售，目前已在全球拥有15万+用户，畅销海内外80余个国家和 地区，长期霸榜亚马逊智能戒指品类销售榜TOP2。 智能戒指，健康管理赛道的新宠 近年来，人们对自身健康管理的重视程度达到了前所未有的高度，对智能穿戴设备的功能和体验也提出了更高要 求。传统的智能手表和手环虽然功能丰富，但在一些方面仍存在局限性。例如，手表体积较大且比较重，长时间 佩戴可能会给手腕带来压迫感，尤其是在睡眠时，不适感更为明显；而且部分手表续航能力不足，需要频繁充 电，导致健康数据记录不连续。 正是在这样的背景下，智能戒指应运而生。它以小巧的体积和无感佩戴的特性，解决了传统设备的诸多痛点。由 于佩戴在手指上，智能戒指不会给身体带来过多负担，即使在睡眠、工作等场景下，也几乎让人感觉不到它的存 在。 同时，智能戒指凭借更贴近血管末梢的位置优势，能够更精确地采集心率、血氧等生理数据，为健康监测提供更 可靠的依据。智能戒指独特的形态和功能，让它在健康管理赛道上迅速崭露头角，成为众多消费者关注的焦点。 在科技与生活深度融合的当下，智能穿戴设备市场呈现出一派繁荣的景象。过去，人们印象中的智能穿戴设 ...

高纯度 Omega-3丨 白皮书 核心摘要： 在健康中国战略全面推进的背景下，国民健康管理意识显著提升，健康需求从 "被动治疗"向"主动预防"加 速转型。随着慢性病防控与亚健康改善成为全民健康的核心议题，膳食营养补充剂已成为全民健康管理的重 要工具，其市场发展与科学认知深化同步推进。基于这一现状，本白皮书旨在深入探讨高纯度 Omega-3 在中国居民健康管理中的作用及应用现状，加强公众对其生理功效的认知，为公众提供更加专业的营养指 导。白皮书从以下五个章节展开： 一、中国居民健康管理现状 国家政策推动全民健康管理向主动预防转型，面对慢性病年轻化与全周期防护挑战，需构建监测、干预与营 养支持体系。膳食营养补充剂通过定向支持和免疫力提升，成为公众践行主动健康管理的核心工具，助力实 现从治疗到预防的跨越。 二、膳食营养补充剂市场认知及应用表现 在国民健康管理需求升级与膳食营养补充剂市场快速发展的双轮驱动下，服用膳食营养补充剂已进阶为现代 人健康管理的核心方案。在消费者决策矩阵中，产品本身与品牌背书构成购买双引擎。但不同人群对成分需 求呈现差异化特征，折射精准健康管理趋势。 三、 Omega-3 产品与应用现状 Om ...

RadNet (RDNT) Q1 2025 Earnings Call May 12, 2025 10:30 AM ET Company Participants Mark Stolper - EVP & CFOHoward Berger - Chairman, President & CEOGrayson McAlister - Equity Research AssociateAndrew Mak - Vice PresidentBrandon Carney - Senior Research Associate Conference Call Participants Brian Tanquilut - Equity Research Analyst - Healthcare ServicesLarry Solow - Partner & Managing director - Equity Analyst Operator Good day, and welcome to the RadNet, Inc. First Quarter twenty twenty five Financial Resul ...

Financial Data and Key Metrics Changes - For Q1 2025, RadNet reported total revenue of $471.4 million, an increase of $39.7 million or 9.2% compared to Q1 2024. Adjusted EBITDA was $46.4 million, a decrease of $12.1 million or 20.6% year-over-year [21][22] - Adjusting for the estimated $22 million impact from severe weather and wildfires, revenue would have increased by 14.3% year-over-year. Adjusted EBITDA, accounting for a $15 million impact, would have increased by 5% [22] - The company ended Q1 2025 with a cash balance of $717 million and a net debt to adjusted EBITDA ratio of slightly more than one [17][24] Business Line Data and Key Metrics Changes - The Digital Health segment reported revenue of $19.2 million, a 31.1% increase year-over-year, with adjusted EBITDA of $3.7 million, up 5.4% [22][23] - AI revenue within Digital Health grew by 33.3%, driven by improved adoption of the EBCD program [23] - PET CT volumes increased by 22.9%, attributed to the growth of newer prostate and brain procedures [8] Market Data and Key Metrics Changes - The company experienced a gradual shift towards advanced imaging, with 26.9% of procedural volume coming from advanced imaging in Q1 2025, compared to 25.7% in Q1 2024 [7] - The adoption rate of the EBCD program reached over 40% nationally, indicating strong market acceptance [12] Company Strategy and Development Direction - RadNet is focused on expanding its digital health initiatives, including the TechLive remote technologist solution and the EBCD AI-powered breast cancer screening program [10][12] - The company announced the acquisition of iCAD Inc, aiming to enhance its AI-powered breast health solutions and expand its market presence [14][15] - RadNet plans to open 11 new centers by the end of 2025 and has a robust pipeline for joint ventures and acquisitions [16][18] Management's Comments on Operating Environment and Future Outlook - Management noted that the severe weather conditions in early 2025 negatively impacted performance but expressed confidence in recovery and strong growth trends in subsequent months [6][9] - The company anticipates continued growth in advanced imaging and routine imaging, driven by technological advancements and increased demand [41][43] - Management expects to see improved margins due to the growth of advanced imaging and the implementation of AI tools [75] Other Important Information - The company has an active pipeline of acquisitions and is evaluating opportunities to advance its strategic objectives [18] - RadNet's liquidity position remains strong, with full availability of a $282 million revolving credit facility [23] Q&A Session Summary Question: What is the outlook for growth in advanced imaging over the next few years? - Management expects growth in advanced imaging to continue, driven by AI tools and new equipment investments [39][41] Question: Can you provide insights on the M&A pipeline? - The pipeline is robust, with ongoing discussions with hospitals recognizing the value of RadNet's radiology solutions [44][46] Question: What are the trends in technologist hiring? - There are improvements in hiring trends, and the company remains comfortable with the projected $45 million increase in labor costs [52][58] Question: How did revenue perform against internal expectations? - Revenue was strong and aligned with internal guidance, with a bounce back in March after weather-related impacts [66][67] Question: What is driving the expected increase in EBITDA margins? - Growth in advanced imaging and the implementation of AI programs are primary drivers for improved margins [75] Question: What is the status of stock-based compensation? - The increase in stock-based compensation is due to vesting from past years and new hires, but it is expected to decrease in subsequent quarters [76]

iRhythm (IRTC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor RelationsQuentin Blackford - President, CEO & DirectorDaniel Wilson - CFOAllen Gong - Vice PresidentMacauley Kilbane - Equity Research AssociateSuraj Kalia - Managing DirectorJon Young - DirectorRichard Newitter - Managing Director Conference Call Participants Kallum Titchmarsh - AnalystNone - AnalystNathan Treybeck - AnalystDavid Rescott - Senior Research AnalystDavid Saxon - Senio ...

Avalon's KetoAir™ breathalyzer used to maintain progress for law enforcement to establish and meet their BrAce goals during the ongoing BrAce 4 Impact Challenge FREEHOLD, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced the addition of SpecialtyHealth, Inc. ("SpecialtyHealth") — co-founded by Dr. EJ Greenwald, the pioneer of the ...

Nutex Health Inc. (NUTX) Q4 2024 Earnings Conference Call April 01, 2025 10:30 AM ET Company Participants Conference Operator - OperatorJennifer Rodriguez - Investor Relations HostDr. Tom Vo - Chairman, Founder & Chief Executive OfficerJohn Bates - Chief Financial OfficerDr. Warren Hosinian - PresidentJosh Dottilio - Chief Operating Officer Conference Call Participants Bill Sutherland - Analyst, The Benchmark CompanyCarl Burns - Analyst, Northland Capital MarketsAnthony Landetti - Analyst, Maxim GroupGene M ...